

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446

Status	RECRUITING
Phase	Phase 2
Sponsor	Nocion Therapeutics
Enrollment	455 participants

Key Eligibility Criteria

Inclusion (4)

- Refractory or unexplained chronic cough for e 12 months.
- Women of childbearing potential agree to follow the protocol specified contraceptive - guidance during the study.
- Males who are not vasectomized must agree to use the contraceptive methods defined in the protocol.
- Able to provide Informed Consent.

Exclusion (15)

- Previous exposure to taplucainium (formerly NTX-1175) or known allergy or hypersensitivity to taplucainium, its excipients/metabolites, or related compounds.
- Participants who are currently participating in another drug or device clinical study
- Participants who have participated in an Acute or Chronic Cough investigational study within 60 days before the start of the Screening.
- Current diagnosis of chronic obstructive pulmonary disease, bronchiectasis, unexplained pulmonary fibrosis, hemoptysis, bronchial asthma, or other pulmonary disease.
- Respiratory tract infection within 4 weeks of Screening or during screening period.

... and 10 more (see full listing online)

Locations (107 total)

G & L Research, LLC, Foley, Alabama, United States
Medical Research of Arizona, Scottsdale, Arizona, United States
AMR Phoenix, Tempe, Arizona, United States
... and 104 more locations